Rapport Therapeutics Inc RAPP
$48.24 $0.39 (0.82%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
RAPP Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Rapport Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Rapport Therapeutics Inc. Stock Analysis RAPP
United States Health Care Mid Cap Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. The company is headquartered in Boston, Massachusetts and currently employs 84 full-time employees. The company went IPO on 2024-06-07. The company has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The company is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Rapport Therapeutics Inc (RAPP) Chart
Financial Metrics & Statements of Rapport Therapeutics Inc (RAPP)
FAQ's for Rapport Therapeutics Inc (RAPP)
- As of August 2026, Rapport Therapeutics Inc RAPP is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Rapport Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Rapport Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Rapport Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Rapport Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Rapport Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Rapport Therapeutics Inc (RAPP)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
